日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/06/21 | 1,578 | 1,580 | 1,561 | 1,575 | +9 | +0.6% | 6,200 |
| 2024/06/20 | 1,578 | 1,578 | 1,566 | 1,566 | -12 | -0.8% | 600 |
| 2024/06/19 | 1,580 | 1,580 | 1,573 | 1,578 | +4 | +0.3% | 800 |
| 2024/06/18 | 1,573 | 1,574 | 1,573 | 1,574 | +5 | +0.3% | 300 |
| 2024/06/17 | 1,582 | 1,582 | 1,569 | 1,569 | -11 | -0.7% | 1,000 |
| 2024/06/14 | 1,569 | 1,580 | 1,567 | 1,580 | +13 | +0.8% | 2,800 |
| 2024/06/13 | 1,568 | 1,574 | 1,567 | 1,567 | +1 | +0.1% | 900 |
| 2024/06/12 | 1,578 | 1,578 | 1,565 | 1,566 | -12 | -0.8% | 800 |
| 2024/06/11 | 1,578 | 1,583 | 1,570 | 1,578 | +14 | +0.9% | 1,900 |
| 2024/06/10 | 1,565 | 1,583 | 1,564 | 1,564 | -18 | -1.1% | 3,600 |
| 2024/06/07 | 1,563 | 1,583 | 1,563 | 1,582 | ±0 | ±0% | 1,100 |
| 2024/06/06 | 1,563 | 1,582 | 1,563 | 1,582 | +17 | +1.1% | 900 |
| 2024/06/05 | 1,573 | 1,593 | 1,559 | 1,565 | -6 | -0.4% | 5,100 |
| 2024/06/04 | 1,556 | 1,571 | 1,556 | 1,571 | +6 | +0.4% | 1,600 |
| 2024/06/03 | 1,572 | 1,576 | 1,556 | 1,565 | ±0 | ±0% | 1,800 |
| 2024/05/31 | 1,564 | 1,571 | 1,557 | 1,565 | +9 | +0.6% | 1,800 |
| 2024/05/30 | 1,565 | 1,565 | 1,556 | 1,556 | -6 | -0.4% | 3,400 |
| 2024/05/29 | 1,573 | 1,573 | 1,562 | 1,562 | -18 | -1.1% | 1,500 |
| 2024/05/28 | 1,581 | 1,581 | 1,566 | 1,580 | -1 | -0.1% | 2,100 |
| 2024/05/27 | 1,592 | 1,592 | 1,563 | 1,581 | +6 | +0.4% | 4,200 |
| 2024/05/24 | 1,559 | 1,575 | 1,559 | 1,575 | +3 | +0.2% | 1,200 |
| 2024/05/23 | 1,567 | 1,572 | 1,567 | 1,572 | +5 | +0.3% | 1,700 |
| 2024/05/22 | 1,568 | 1,568 | 1,559 | 1,567 | -1 | -0.1% | 1,000 |
| 2024/05/21 | 1,570 | 1,575 | 1,559 | 1,568 | +6 | +0.4% | 5,000 |
| 2024/05/20 | 1,575 | 1,576 | 1,562 | 1,562 | -4 | -0.3% | 3,000 |
| 2024/05/17 | 1,568 | 1,568 | 1,566 | 1,566 | -4 | -0.3% | 2,800 |
| 2024/05/16 | 1,597 | 1,597 | 1,570 | 1,570 | -16 | -1% | 3,400 |
| 2024/05/15 | 1,600 | 1,600 | 1,577 | 1,586 | +3 | +0.2% | 2,500 |
| 2024/05/14 | 1,590 | 1,590 | 1,570 | 1,583 | -17 | -1.1% | 13,500 |
| 2024/05/13 | 1,601 | 1,610 | 1,600 | 1,600 | -14 | -0.9% | 3,100 |
| 2024/05/10 | 1,611 | 1,619 | 1,603 | 1,614 | +3 | +0.2% | 1,700 |
| 2024/05/09 | 1,602 | 1,611 | 1,602 | 1,611 | +10 | +0.6% | 800 |
| 2024/05/08 | 1,608 | 1,613 | 1,601 | 1,601 | -22 | -1.4% | 4,200 |
| 2024/05/07 | 1,619 | 1,627 | 1,610 | 1,623 | +13 | +0.8% | 1,500 |
| 2024/05/02 | 1,594 | 1,612 | 1,594 | 1,610 | +10 | +0.6% | 1,800 |
| 2024/05/01 | 1,592 | 1,609 | 1,592 | 1,600 | +9 | +0.6% | 2,400 |
| 2024/04/30 | 1,590 | 1,620 | 1,590 | 1,591 | +1 | +0.1% | 5,200 |
| 2024/04/26 | 1,606 | 1,612 | 1,590 | 1,590 | -22 | -1.4% | 18,700 |
| 2024/04/25 | 1,614 | 1,616 | 1,608 | 1,612 | +7 | +0.4% | 2,400 |
| 2024/04/24 | 1,602 | 1,622 | 1,602 | 1,605 | +3 | +0.2% | 6,400 |
| 2024/04/23 | 1,603 | 1,610 | 1,602 | 1,602 | +1 | +0.1% | 1,000 |
| 2024/04/22 | 1,608 | 1,608 | 1,601 | 1,601 | ±0 | ±0% | 900 |
| 2024/04/19 | 1,606 | 1,610 | 1,601 | 1,601 | -13 | -0.8% | 2,800 |
| 2024/04/18 | 1,610 | 1,614 | 1,602 | 1,614 | +10 | +0.6% | 1,700 |
| 2024/04/17 | 1,607 | 1,627 | 1,602 | 1,604 | -1 | -0.1% | 2,400 |
| 2024/04/16 | 1,622 | 1,645 | 1,605 | 1,605 | -20 | -1.2% | 3,300 |
| 2024/04/15 | 1,635 | 1,635 | 1,621 | 1,625 | -20 | -1.2% | 3,000 |
| 2024/04/12 | 1,641 | 1,647 | 1,629 | 1,645 | +4 | +0.2% | 3,900 |
| 2024/04/11 | 1,631 | 1,645 | 1,631 | 1,641 | +10 | +0.6% | 2,400 |
| 2024/04/10 | 1,637 | 1,637 | 1,628 | 1,631 | -6 | -0.4% | 2,300 |
251～
300
件表示中 / 3732件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 147,000円 | +7.5% | -77.4% | 3.40% | 35.36倍 | 0.28倍 |
|
後発薬中堅、検査薬事業が第２の柱に。提携含めた新薬開発、ベトナムなど海外事業を中期強化 |
| サイフューズ | 81,200円 | +459.3% | - | 0.00% | - | 2.61倍 |
|
バイオ３Ｄプリンタを開発、自家細胞製品の製造受託も。臓器など再生医療等製品を臨床開発中 |
| カルナバイオ | 33,600円 | +13.5% | - | 0.00% | - | 2.68倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| モダリス | 8,000円 | - | - | 0.00% | - | 1.79倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
| ペルセウス | 40,900円 | +25.0% | - | 0.00% | - | 4.38倍 |
|
東大発バイオベンチャー。高機能抗体の取得に強み。抗体医薬品や抗体薬物複合体（ＡＤＣ）開発 |
市場注目の銘柄
チャート関連のコラム
